



## Bicycle Therapeutics to Present New Translational Research for BT5528 and Preclinical Data for Tumor-targeted Immune Cell Agonists at the AACR Virtual Annual Meeting II

May 15, 2020

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--May 15, 2020-- [Bicycle Therapeutics plc](#) (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that new translational research for second-generation *Bicycle*® Toxin Conjugate (BTC) BT5528 and preclinical data for novel, fully synthetic tumor-targeted immune cell agonists (TICAs™) BT7480 and BT7455 will be presented during poster sessions at the American Association for Cancer Research (AACR) Virtual Annual Meeting II on June 22-24, 2020. All e-posters will be made available for browsing on AACR's e-poster website starting June 22.

BT5528 is a second-generation BTC, which uses a valine-citrulline cleavable linker and a cytotoxin MMAE payload, that targets EphA2, a tumor antigen that is overexpressed in a wide range of solid tumor types and is associated with poor outcomes. BT7480 is a TICA targeting tumor antigen Nectin-4 and agonizing CD137 (4-1BB). BT7455 is a TICA targeting EphA2 and agonizing CD137.

Details on Bicycle's poster presentations at AACR are as follows:

**Session Title:** Molecular Classification of Tumors for Diagnostics, Prognostics, and Therapeutic Outcomes 2

**Session Category:** Experimental and Molecular Therapeutics

**Poster Title:** A survey of EphA2 expression by immunohistochemistry (IHC) in tumor tissue microarrays (TMAs) to support BT5528 indication selection

**Abstract #:** 3302

**Session Title:** Immunomodulatory Agents and Interventions 2

**Session Category:** Immunology

**Poster Title:** BT7480, a novel fully synthetic tumor-targeted immune cell agonist (TICA™) induces tumor localized 4-1BB agonism

**Abstract #:** 5241

**Session Title:** Immunomodulatory Agents and Interventions 3

**Session Category:** Immunology

**Poster Title:** A fully synthetic EphA2/4-1BB tumor-targeted immune cell agonist (TICA™) induces tumor localized 4-1BB agonism

**Abstract #:** 4613

The posters will be available on the Publications section of [bicycletherapeutics.com](#) following presentation.

### About Bicycle Therapeutics

Bicycle Therapeutics (NASDAQ: BCYC) is a clinical-stage biopharmaceutical company developing a novel class of medicines, referred to as *Bicycles*®, for diseases that are underserved by existing therapeutics. *Bicycles* are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. This constraint facilitates target binding with high affinity and selectivity, making *Bicycles* attractive candidates for drug development. Bicycle's lead product candidate, BT1718, a *Bicycle* Toxin Conjugate (BTC) that targets MT1-MMP, is being investigated in an ongoing Phase I/IIa clinical trial in collaboration with the Centre for Drug Development of Cancer Research UK. Bicycle is also evaluating BT5528, a second-generation BTC targeting EphA2, in a Company-sponsored Phase I/II study. Bicycle is headquartered in Cambridge, UK with many key functions and members of its leadership team located in Lexington, MA. For more information, visit [bicycletherapeutics.com](#).

View source version on [businesswire.com](#): <https://www.businesswire.com/news/home/20200515005111/en/>

### Investor and Media:

Bicycle Therapeutics

Maren Killackey

[maren.killackey@bicyclttx.com](mailto:maren.killackey@bicyclttx.com)

+1-617-203-8300

Source: Bicycle Therapeutics plc